Ardelyx Reports Q3 Financial With IBSRELA Revenue Growth
Ardelyx reported third-quarter product revenue of $125.5 million, driven by 23% growth in its IBSRELA franchise. The biopharmaceutical company also announced full-year guidance and provided updates on its Phase 3 ACCEL trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed